Submission of Consolidated Voting Results and Scrutinizer''s Report on all the resolutions as set out in the notice convening the 40th AGM of the Company held on 18th July, 2025.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Jenburkt Pharmaceuticals held its 40th AGM on July 18, 2025 via video conferencing, with all 6 resolutions passed with the required majority. Shareholders approved the audited financial statements for FY 2024-25, declared a dividend of Rs. 18.00 per share (180%) on Rs. 10 face value, re-appointed Shri Ashish U. Bhuta as Director (retiring by rotation) and as Chairman & Managing Director, appointed Secretarial Auditors for a 5-year term, and ratified the Cost Auditor's remuneration for FY 2025-26. Out of 4,413,300 total outstanding shares, about 2,007,854 votes (45.5%) were polled, with promoter group accounting for 1,965,590 votes and public non-institutions 42,264. All resolutions passed with 100% approval except the Managing Director re-appointment which saw 99.99% in favour (50 votes against). 67 shareholders attended via VC; 7,97,607 promoter votes were treated as invalid/abstained on resolutions where the promoter group had an interest.
The headline takeaway for shareholders is the 180% dividend (Rs. 18 per share), which signals strong cash generation and shareholder reward. Unanimous approval across all resolutions, including the re-appointment of the promoter-Chairman, indicates stable management continuity with no visible shareholder dissent.